Abstract
Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. Patients with advanced solid malignancies and hepatic impairment were enrolled into one of four cohorts: normal [bilirubin (bili) < upper limit of normal (ULN)], mild (ULN < bili ≤ 1.5 × ULN), moderate (1.5 × ULN < bili ≤ 3×ULN), and severe (3 × ULN < bili < 10 × ULN) dysfunction. Patients received oral vismodegib 150 mg daily. Plasma PK samples on days 1, 3, 5, and 8 were collected. Vismodegib therapy was continued until disease progression, intolerable toxicity, or withdrawal of consent. Thirty-one patients were accrued: nine normal, eight mild, eight moderate, and six severe. Four patients experienced dose-limiting toxicity of hyperbilirubinemia on study: one in the moderate cohort and three in the severe cohort. Six patients died within 30 days after the last dose of vismodegib. All deaths were attributed to disease progression. Observed maximal and average steady-state concentrations and AUC of vismodegib at steady state (day 8) were similar across cohorts. Average AAG concen...Continue Reading
References
Dec 4, 2001·Genes & Development·P W Ingham, A P McMahon
Jan 23, 2004·Nature Reviews. Cancer·Marina Pasca di Magliano, Matthias Hebrok
Jun 17, 2005·Cancer Research·Justyna Romer, Tom Curran
Oct 5, 2007·The Oncologist·Diana SuperfinAngela M Davies
Aug 30, 2008·Nature·Robert L YauchFrederic J de Sauvage
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 23, 2010·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·X DingC E C A Hop
Feb 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LoRussoDaniel D Von Hoff
May 24, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Richard A GrahamCornelis E C A Hop
Jun 28, 2011·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Yuzhong DengBrian Dean
Jun 8, 2012·The New England Journal of Medicine·Aleksandar SekulicAxel Hauschild
Apr 5, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Manish R SharmaEzra E W Cohen
Jan 20, 2016·CPT: Pharmacometrics & Systems Pharmacology·T LuJ Y Jin
May 8, 2016·Cancer Chemotherapy and Pharmacology·Vikram MalhiRichard A Graham
Citations
Feb 15, 2019·Cells·Daniel GirardiAllan Pereira
Jun 13, 2019·Journal of Clinical Pharmacology·Linh NguyenSteven Lacy
Aug 28, 2019·Angewandte Chemie·Lea KremerHerbert Waldmann
Oct 28, 2019·Clinical Pharmacokinetics·Belén P SolansIñaki F Trocóniz
May 28, 2020·Journal of Hematology & Oncology·Yue YangLufeng Zheng
Jul 22, 2018·Drugs·James E Frampton, Nicole Basset-Séguin
Apr 18, 2019·Medical Oncology·Anne-Laure ClairetSamuel Limat
Feb 7, 2020·Pulmonary Therapy·Antje PrassePeter P LaCamera
Sep 4, 2020·World Journal of Clinical Oncology·Ariel Ka-Man ChowLui Ng
Sep 24, 2020·International Journal of Molecular Sciences·Kuo-Shyang JengChiung-Fang Chang
Apr 29, 2021·Cancer Chemotherapy and Pharmacology·Nikolay GrechkoJim Xiao